Rosenblatt Maintains Sell on CME Gr, Raises Price Target to $173
Portfolio Pulse from richadhand@benzinga.com
Rosenblatt analyst Andrew Bond maintains a 'Sell' rating on CME Group (NASDAQ:CME) and raises the price target from $169 to $173.
July 27, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rosenblatt analyst maintains a 'Sell' rating on CME Group but raises the price target from $169 to $173.
The 'Sell' rating maintained by Rosenblatt indicates a negative outlook for CME Group. However, the increase in price target from $169 to $173 suggests that the analyst sees some upside potential, albeit not enough to change the overall negative rating. This could lead to short-term downward pressure on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100